NFE2L2 and head and neck cancer: Bai et al. (2019) confirmed that activating the NRF2 pathway suppressed ferroptosis in a hepatocellular carcinoma (HCC) mouse model. Erastin and sorafenib can trigger ferroptosis by inactivating NRF2–KRAP1 complex. Recently, a study carried out by Roh et al. (2017) showed that NRF2 inhibition increased sensitivity of both head and neck cancer to ferroptosis. A study showed that suppressing the SQSTM1–KEAP1–NRF2 pathway facilitated ferroptosis in HCC cells with co-treatment of erastin and sorafenib (Inami et al., 2011).